OA16894A - Assembly for an inhaler. - Google Patents

Abstract

An assembly for an inhaler is disclosed which provides excellent feedback to the user and is particularly suitable to be used with certain medical substances or pharmaceutical compositions.

Description

The présent disclosure relates to an assembly, particularly an assembly for an inhaler, such as a dry powder inhaler.

It is an object of the présent disclosure to provide an assembly which facilitâtes provision of an improved, preferably reliably working, inhaler. Particularly, It is an aim to provide an inhaler with excellent user-feedback features, preferably especially for treating certain dîseases. Furthermore the disclosure relates to certain pharmaceutical compositions and their use in a device containing them, particularly for the treatment of asthma and COPD.

This object is achieved by an assembly as speclfied further In the daims. Further advantages and refinements are subject matter of the dépendent daims and also of the following disclosure. The following disclosure may also cover embodiments which are currently not being claimed or which are broader than the currently claimed subject matter.

One aspect of this disclosure relates to an assembly for an inhaler. A further aspect of this disclosure relates to an inhaler comprising the assembly. Accordingly, the features disclosed below In connection with the assembly also apply for the inhaler and vice 25 versa.

In an embodiment, the assembly comprises a storage chamber. A powdery substance may be arranged within the storage chamber. The powdery substance may comprise a medical substance. The medical substance may comprise a pharmaceutically acitve ingrédient (API) and a carrier for the API, e.g. lactose.

The term “medical substance, as used herein may mean a pharmaceutical formulation or composition containing at least one pharmaceutically active compound, for example for the treatment of obstructive airway or lung dîseases such as asthma or chronic obstructive pulmonary disease (COPD), local respiratory tract oedema, Inflammation, viral, bacterial, mycotic or other infection, allergies, diabètes mellitus.

The active pharmaceutical compound is preferably selected from the group consisting of 5 active pharmaceutical compounds suitable for inhalation, preferably antiallergenic, antihistamine, anti-inflammatory, antitussive agents, bronchodilators, anticholinergic drugs, and combinations thereof.

The active pharmaceutical compound may for example be chosen from:

an insulin such as human insulin, e.g. a recombinant human insulin, or a human insulin analogue or dérivative, a glucagon-like peptide (GLP-1) or an analogue or dérivative thereof, or exendin-3 or exendin-4 or an analogue or dérivative of exendin-3 or exendin4;

an adrenergic agent such as a short acting p2-agonists (e.g. Salbutamol, Albuterol, Levosalbutamol, Fenoterol, Terbutaline, Pirbuterol, Procaterol, Bitolterol, Rimiterol, Carbuterol, Tulobuterol, Reproterol), a long acting p2-agonist (LABA, e.g. Arformoterol, Bambuterol, Clenbuterol, Formoterol, Salmeterol), an ultra LABA (e.g. Indacaterol) or another adrenergic agent (e.g. Epinephrine, Hexoprenaline, Isoprénaline (Isoproterenol), Orciprenaline (Metaproterenol));

a glucocorticoid (e.g. Beclometasone, Budesonide, Ciclesonide, Fluticasone, Mometasone, Flunisolide, Betamethasone, Triamcinolone);

an anticholinergic agent or muscarinic antagonist (e.g. Ipratropium bromide, Oxitropium bromide, Tiotropium bromide);

a mast cell stabilizer (e.g. Cromoglicate, Nedocromil);

a xanthine dérivative (e.g. Doxofylline, Enprofÿlline, Theobromine, Theophylline, Aminophylline, Choline theophyllinate);

an eicosanoid inhibitor, such as a leukotriene antagonist (e.g. Montelukast, Pranlukast, Zafirlukast), a lipoxygenase inhibitor (e.g. Zileuton) or a thromboxane receptor antagonist (e.g. Ramatroban, Seratrodast);

a phosphodiesterase type-4 inhibitor (e.g. Roflumilast);

an antihistamine (e.g. Loratadine, Desloratadine, Cetirizen, Levocetirizine, Fexofenadine);

an allergen immunotherapy (e.g. Omalizumab);

a mucolytic (e.g. Carbocisteine, Erdosteine, Mecysteine);

an antibiotic or antimycotic;

or a combination of any two, three or more of the above-mentioned compound classes or compounds (e.g. Budesonide/Formoterol, Fluticasone/Salmeterol, Ipratropium bromide/Salbutamol, Mometasone/Formoterol);

or a pharmaceutically acceptable sait or solvaté or esters of any of the above named compounds.

Pharmaceutically acceptable salts are for example acid addition salts and basic salts. Acid addition salts are e.g. a chloride, bromide, iodide, nitrate, carbonate, sulfate, 25 methylsulfate, phosphate, acetate, benzoate, benzenesulfonate, fumarate, malonate, tartrate, succinate, citrate, lactate, gluconate, glutamate, edetate, mesylate, pamoate, pantothenate or a hydroxy-naphthoate sait. Basic salts are for example salts having a cation selected from alkali or alkaline, e.g. Na+, or K+, or Ca2+, or an ammonium ion N+(R1)(R2)(R3)(R4), wherein R1 to R4 independently of each other mean: hydrogen, 30 an optionally substituted C1 C6-alkyl group, an optionally substituted C2-C6-alkenyl group, an optionally substituted C6-C10-aryl group, or an optionally substituted C6-C10heteroaryl group. Further examples of pharmaceutically acceptable salts are described in Remington's Pharmaceutical Sciences 17. ed. Alfonso R. Gennaro (Ed.), Mark Publishing Company, Easton, Pa., U.S.A., 1985 and in Encyclopédie of Pharmaceutical

Technology. Pharmaceutically acceptable ester may for example be acétates, propionates, phosphates, succinates or etabonates.

Pharmaceutically acceptable solvatés are for example hydrates.

In an embodiment, the powdery substance comprises one or more pharmaceutically active ingrédients (APIs), e.g. of the ones recited further above or below. The powdery substance may comprise a pharmaceutical composition, the composition comprising the API(s) and, preferably, a carrier for the API. The carrier may be or may comprise lactose.

Generally, the API(s) mentioned herein may be suitable for treating of different diseases, among others pulmonary diseases for example asthma, COPD or bronchitis.

ln an embodiment, the one or more APIs are selected from levalbuterol, reproterol, clen bute roi, bambuterol.broxaterol salmeterol xinafoate, fluticasone propionate, budesonide, salbutamol, beclomethasone, formoterol, terbutalin salmeterol, tulobuterol, indacaterol, isoprénaline, hexoprenaline, tiotropium, ipatropium, oxitropium, fenoterol, mometason, ciclesonid and rofleponid.

The assembly for the inhaler proposed herein has been found to be particularly useful for being used for the inhalation of the substances, formulations and compositions mentioned further above and below.

In an embodiment, the powdery substance comprises the combination of salmeterol xinafoateffluticasone propionate as APIs.

It is known that the combinations of salmeterol xinafoate and fluticasone propionate are suitable for the treatment of asthma and COPD. They are applicable in the form of dry inhalable powder formulations where the pharmaceutically acceptable carriers may be among others lactose, glucose, maltose, fructose, sucrose, dextrose, their hydrates or mixtures thereof.

It has been found that combination of salmeterol xinafoate and fluticasone propionate in the form of certain dry inhalable powder formulations where the pharmaceutically acceptable carriers may be among others lactose, glucose, maltose, fructose, sucrose, dextrose, their hydrates or mixtures thereof applied filled into the inhalation devices provide unexpectedly better bioavailability / tissue level and thus unexpectedly better therapeutic efficacy than the known formulations / Seretide Discus mite and others.

It has further been found that a pharmaceutical composition as disclosed above and below is particularly suitable for being used with the assembly for the inhaler or the inhaler described herein, for example as it provides better bioavailability so as compared to other devices delivering the same API combination. The better bioavailability was only discovered when the composition was tested in the inhaler disclosed herein. This suggests that the combination of the composition with the inhaler has considérable advantages.

In an embodiment, the pharmaceutical composition, which is in particular suitable for use in a dry powder inhaler comprises:

- at least one pharmaceutically acceptable carrier, e.g. lactose, suitable for use in dry powder inhalation formulations and

- salmeterol xinafoate and fluticasone propionate as pharmaceutically active ingrédients (APIs).

In an embodiment there is provided a method of making the pharmaceutical composition comprising the following steps:

(i) first part of a carrier and salmeterol xinafoate are blended together, (ii) second part of the carrier and fluticasone propionate are blended together a mixture is prepared, (iii) mixtures received in steps (i) and (ii) are blended together, and (iv) the received dry powder mixture in step (iv) is filled into the storage chamber.

In an embodiment, the assembly for the inhaler is used in conjunction with the above pharmaceutical composition for the treatment of asthma and/or COPD.

In the following text, embodiments of the pharmaceutical composition are described. The embodiments use numbers to facilitate references of the features of one embodiment in other embodiments.

1. A pharmaceutical composition comprising 70 mass% - 99,5 mass% of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0,1 mass% - 12,5 mass% of salmeterol xinafoate and 0,4 mass% -17,5 mass% of fluticasone propionate.

2. The pharmaceutical composition according to embodiment 1, comprises 88 mass% - 99,2 mass% of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0,3 mass% - 5,0 mass% of salmeterol xinafoate and 0,5 mass% - 7,0 mass% of fluticasone propionate.

3. The composition according to embodiment 1 wherein the pharmaceutically acceptable carrier is selected from lactose, glucose, maltose, fructose, sucrose, dextrose, their hydrates or mixtures thereof.

4. The composition according to any preceding embodiment comprises lactose or its hydrate as a pharmaceutically acceptable carrier.

5. The composition according to any preceding embodiment wherein the composition comprises lactose monohydrate having particle size distribution of D10 = 60-115 micrometer, D50 = 135-200 micrometer, D90 is bigger than 220 micrometer and salmeterol xinafoate having particle distribution of D10 less than 2 micrometer, D50 less than 3-6 micrometer, D90 less than 20 micrometer, D99 less than 50 micrometer and fluticasone propionate having particle distribution of D10 less than 1,3 micrometer, D50 less than 4,0 micrometer, D90 less than 10 micrometer, D99 less than 50 micrometer.

In the following text the assembly for the inhaler is described in more detail.

In an embodiment. the assembly comprises a mouthpiece. The mouthpiece may be provided for interaction with a user. The user may Internet with the mouthpiece, e.g. by placing his lips around the mouthpiece, to perform a user suction action for inhalation. The suction action may generate a suction airstream which may flow from an air inlet of the assembly towards the mouthpiece through a flow channel which can be established between the air inlet and the mouthpiece.

In an embodiment, the assembly comprises a metering rod which îs provided with a metering chamber. The metering chamber is designed to retain a sub-quantity of the powdery substance. The metering chamber may be a transverse bore extending through the metering rod. The metering chamber is expediently moveable relative to the storage chamber to retrieve the sub-quantity of the powdery substance from the storage chamber and to move the sub-quantity into a transfer location outside the storage chamber. In the transfer location, the sub-quantity may be arranged to be retrieved from the metering chamber and to be moved to the mouthpiece by the suction airstream. The movement from the storage chamber to the transfer location may comprise concurrent axial and rotational movement of the metering chamber with respect to the storage chamber. In this way, a reliable filling of the metering chamber with powder is facilitated. The metering chamber is expediently arranged offset from the axis around which it rotâtes during its movement from the storage chamber towards the transfer location.

In an embodiment, the assembly comprises a piston. The piston is expediently moveable relative to the metering rod between a blocking position and a non-blocking position. In the blocking position, the flow channel may be blocked by the piston. In the non-blocking position, air is permitted to flow from the air inlet to the mouthpiece via the flow channel. The movement of the piston may expediently be actuated by the user suction action. When the piston is in the blocking position, the piston may cover the metering chamber. Consequently, the sub-quantity of the powdery substance is protected by the piston when it is in the transfer location, e.g. from moisture or from falling out of the metering chamber. As the movement of the piston may be actuated by the user suction action, the piston may be moved only if an inhalation takes place. Hence, the sub-quantity of substance is exposed to the environment and thus to the moisture in the environment only if the piston is moved to uncover the metering chamber and, consequently, only if an inhalation takes place. Further, it is, on account of the piston, guaranteed that no médicament is lost if the metering chamber remains in the transfer location for a longer time or the assembly is subjected to extemal forces, ' such as by shaking, for example.

In an embodiment, the assembly comprises a closure cap. The closure cap may be disconnectable from the remainder of the assembly and, preferably, re-connectable to the remainder of the assembly. The closure cap may cover the mouthpiece, particularly if it is connected to the remainder of the assembly. Accordingly, the closure cap may protect the interior of the assembly against exposure to environmental influences such as moisture, for example.

The cap may be releasably connected to the metering rod. Consequently, a movement of the closure cap to uncover the mouthpiece may be converted into movement of the metering rod, such as to move the metering chamber into the transfer location. The connection between the metering rod and the closure cap may be released when the metering chamber has reached the transfer location. Once the metering rod is disconnected from the closure cap, the closure cap may be disconnected from the remainder of the assembly. Therefore, the movement for disconnecting the closure cap from the remainder of the device may be utilized to move the sub-quantity of the powdery substance into the transfer location. No extra user action is required for this purpose.

When the closure cap is re-connected to the remainder of the assembly, the connection between the closure cap and the metering rod may be re-established. Also, when the closure cap is reconnected to the remainder of the assembly, the metering chamber may be moved again from the transfer location into the storage chamber. When the connection between the metering rod and the closure cap is re-established, a preferably audible and/or tactile feedback may be generated. In this way, it may be indicated that the closure cap has been re-connected correctly and that the assembly is ready to move the metering chamber again from the storage chamber into the transfer location. Thus, the feedback provides information to the user that the assembly may be used again for performing a further inhalation. An audible feedback may be generated by a snap-fit engagement which is re-established between the closure cap and the metering rod. Again, for moving the metering chamber back into the storage chamber, no extra user action is necessary besides the re-connection of the closure cap to the remainder of the assembly.

In an embodiment, the piston is retained in the non-blocking position after the user suction action. The piston may be retained in this position at least until the closure cap is being reconnected to the remainder of the assembly. During re-connection of the closure cap to the remainder of the assembly, the piston may be moved from the nonblocking position back to the blocking position. For doing so, no extra user action is necessary besides the re-connection of the closure cap to the remainder of the assembly.

In an embodiment, the assembly comprises a window which allows a Visual check to confirm whether the assembly is in a ready-to-inhale state or not. For example, if the assembly is in the ready-to-inhale state, the piston, which is in the blocking position, may be visible through the window. When the closure cap is connected to the remainder of the assembly, the window is expediently covered by the cap and is preferably not visible to the user. For example, the piston may be green. The presence of the piston in the visible area defined by the window signais to the user that the assembly is ready for an inhalation. If the piston is not visible through the window, the window may be black, for example. If the piston is not visible, it may be in the non-blocking position, which is the position after inhalation and before closing the device again by re-connecting the closure cap to the remainder of the assembly.

In an embodiment, the assembly is configured to provide one or more operational feedbacks, such as audible, Visual, tactile and/or inspiratory feedback, to the user. The respective feedback may indicate to the user that the inhalation is being performed correctly or has been performed correctly. Preferably, a plurality of feedbacks is provided to the user. The first of these feedbacks may be the Visual check whether the assembly is in the ready-to-inhale state. The second one may be a feedback which is provided when the piston begins to move from the blocking position to the non-blocking position. This feedback may be an inspiratory feedback as the inspiratory effort required to get the piston moving is greater than the one necessary to keep the piston moving. Accordingly, once the inspiratory effort is reduced, a feedback is glven to the user which indicates that the piston has moved. Once the piston reaches the blocking position, an engagement ofthe piston with an end stop may provide a furtherfeedback, particularly an audible one, to the user that the piston has reached the blocking position. Expediently, the inspiratory effort necessary to move the piston is chosen such that it is guaranteed that the whole sub-quantity of powdery substance retained in the metering chamber is transferred by the suction airstream, which is generated by the user suction action, to the user and is deposited in the user’s lung. The inspiratory effort to move the piston may be adjusted by adjusting the static friction which has to be overcome to move the piston.

In an embodiment, the assembly comprises a housing. The storage chamber may be arranged within the housing. The closure cap may be releasably connected to the housing when it is connected to the remainder of the assembly. Releasing the connection or re-establishing the connection to the housing may require a rotational and preferably a concurrent axial movement ofthe closure cap with respect to the housing. The closure cap, when connected to the housing, may be threadedly engaged with the housing.

In an embodiment, the metering rod is rotated and moved axially with respect to the housing when the metering chamber is moved from the storage chamber into the transfer location.

In an embodiment, the assembly comprises an outer part, such as an outer cylinder, for example. The mouthpiece may be provided on the outer part. The outer part may be uncovered oncethe closure cap has been disconnected fromthe remainderofthe assembly. The outer part may be connected rotatably to the housing. Thus, relative rotation between housing and outer part may be allowed. The outer part may be axially secured with respect to the housing. Thus, relative axial movement between housing and outer part may be prevented or restricted. The closure cap, when connected to the housing, may be rotationally locked to the outer part such that the outer part rotâtes together with the closure cap when the closure cap is disconnected firom the housing. The metering rod may be retained in the outer part. The metering rod may rotate when the outer part rotâtes. Accordingly, when the cap is disconnected, the metering chamber may rotate within the storage chamber, thereby being filled with the sub-quantity of the powdery substance.

In an embodiment, the mouthpiece is coloured differently than a région of the assembly which adjoins the mouthpiece, e.g. the outer part. Consequently, the outer part may be coloured differently than the mouthpiece. In this way, the user knows where to place his/her lips. As the outer part may be provided with one or more additional openings, such as the air inlet, for example, it is important to ensure that the suction action is applied via the mouthpiece only and that the user does not attempt to use a different opening for this purpose.

In an embodiment, the metering rod extends through the piston, with the piston being preferably slidable along the metering rod. The piston may be in frictional contact with the metering rod or not.

In an embodiment, the storage chamber is sealed with respect to the environment. Particularly, the metering rod may comprise a région outside the metering chamber, which is always arranged within the storage chamber. In this way, a guiding opening to the storage chamber may receive the metering rod and always be filled with a part of the metering rod, regardless of whether the metering chamber Is arranged in the transfer location or in the storage chamber. Consequently, the guiding opening may be sealed by means ofthe metering rod and, if applicable, by means of a seal provided in the région ofthe opening and frictionallycooperating with the metering rod to seal the storage chamber. Accordingly, the powdery substance within the storage chamber may be protected against harmful environmental influences like moisture, for example.

In an embodiment, the assembly comprises a first rotational stop feature on the closure cap, the first rotational stop feature providing a first rotational stop face. Further, the assembly may comprise a second rotational stop feature on the remainder of the device, preferably on the housing, the second rotational stop feature providing a second rotational stop face. The first and the second stop faces may extend in an axial direction. The first and the second stop faces may face in the angular direction. The first and the second stop faces are expediently designed to abut each other when the closure cap has reached its end position when being reconnected to the remainder of the assembly.

Thus, the relative arrangement of the first and second stop features may Indicate whether the closure cap has reached its end position. The first and second rotational stop features are preferably arranged to be visible when the closure cap is (re)connected to the remalnder of the assembly, particularly also when the first and the second stop faces abut. ln this way, the user can perform a simple Visual check to confirm that a defined end position of the closure cap has been reached. As the closure cap plays a vital rôle in preparing the assembly for use, this check increases the user confidence in the reliability of the device.

When the closure cap is connected to the housing by means of rotational and preferably concurrent axial movement, the first stop face may be moved towards the second stop face, e.g. along a helical path defined by the threaded connection between housing and closure cap, until the first and second stop faces abut. If the two stop faces abut, no further rotation is possible. Accordingly, this is advantageous as compared to two stop faces which face in the axial direction, for if those stop faces abut, a user might try to rotate the cap further, thereby deforming and destroying the cap. If two angular stop faces abut, the risk of destroying the cap can be considerably reduced.

ln an embodiment, the assembly comprises an indicator which provides information about the amount of powdery substance remaining in the storage chamber. The indicated information may be information directly derived from the fîlling level of the storage chamber. For example, the assembly may comprise an indicator window displaying an indicator that is directly connected to an element which délimite the storage chamber. The indicator window may be visible when the closure cap is connected to the remainder of the assembly. The element which delimits the storage chamber may, for example, be a moveable wall of the storage chamber, which may be spring-biased. Once one or a plurality of sub-quantities of the powdery substance has been removed from the storage chamber, the moveable wall may be moved to keep the powdery substance within the storage chamber compact. The indicator may be moved within the window concurrently with the moveable wall. The position of the indicator within the window may indicate the fîlling level of the storage chamber.

ln an advantageous embodiment, an assembly for an inhaler comprises:

- a storage chamber, in which a powdery substance is arranged;

- a mouthpiece;

- a metering rod provided with a metering chamber, the metering chamber being movable relative to the storage chamber to retrieve a sub-quantity of the powdery substance from the storage chamber and to move the sub-quantity into a transfer location outside the storage chamber, wherein, in the transfer location, the sub-quantity is arranged to be retrieved from the metering chamber and to be moved to the mouthpiece by a suction airstream which is generatable by a user suction action which is performed for an inhalation, the suction airstream flowing through a flow channel which is establishable between an air inlet of the assembly and the mouthpiece;

- a piston which is movable relative to the metering rod between a blocking position, in which the flow channel is blocked by the piston, and a non-blockîng position, in which air is permitted to flow from the air inlet to the mouthpiece via the flow channel, the movement of the piston being actuatable by the user suction action; and

- the powdery substance comprising as a pharmaceutically active ingredient-pair salmeterol xinafoate/fluticasone propionate.

The advantages of this embodiment become apparent from the description above and the description of the exemplary embodiments below.

Further features and expediencies of the disclosure become apparent from the following description of the exemplary embodiment in conjunction with the figures.

Figure 1 shows the vertical section through a metering device according to the invention in its basic position, with the cap closed;

Figure 2 shows a further vertical section along line ll-ll in Figure 1;

Figure 3 shows an enlargement of an upper région of the device according to

Figure 1;

Figure 4 shows a sectîonal illustration corresponding to Figure 1, relating to the situation where the storage chamber for the substance which is to be inhaled has been more or less emptied;

Figure 5	shows the section along line V-V in Figure 4;
Figure 6	shows a further illustration corresponding to Figure 1, this time during removal of the closure cap;
Figure 7	shows the section along line VII-VII in Figure 6;
Figure 8	shows the vertical section according to Figure 1, but following removal of the closure cap and the resulting displacement of a metering chamber into the emptying-standby position;
Figure 9	shows the section along line IX-IX in Figure 8;
Figure 10	shows a detail-view illustration corresponding to Figure 3, relating to the situation according to Figure 8;
Figure 11	shows a follow-up illustration to Figure 8, but relating to a position assumed during inhalation;
Figure 12	shows the section along line XII-XII in Figure 11 ;
Figure 13	shows a further detail-view illustration corresponding to Figure 3, but relating to the situation according to Figure 11;
Figure 14	shows a further vertical-section illustration corresponding to Figure 1, this time relating to an intermediate position as the closure cap is being replaced following completion of inhalation;
Figure 15	shows a follow-up illustration to Figure 14, relating to an intermediate position;
Figure 16	shows a follow-up illustration to Figure 15, relating to an intermediate position as the operation of screwing on the closure cap continues;

Figure 17	shows the cross-section through the metering device in the emptyingstandby position along line XVII-XVII in Figure 8;
Figure 18	shows the cross-sectional illustration through the metering device along line XVIII-XVllI in Figure 11;
Figure 19	shows an illustration which corresponds to Figure 17 and has been taken along line XIX-XIX in Figure 11, relating to the emptying-release position;
Figure 20	shows the section along line XX-XX in Figure 11 through the storage chamber, with the substance which is stored here having been left out;
Figure 21	shows a perspective detail Illustration of an Inner cylinder of the metering device;
Figure 22	shows a further perspective illustration of the inner cylinder;
Figure 23	shows a perspective detail illustration of the metering rod of the metering device;
Figure 24	shows a perspective detail illustration of the piston;
Figure 25	shows a further perspective detail illustration of a rotor-like blade for disposing on the Inner cylinder;
Figure 26	shows a further perspective illustration of the rotor-like blade;
Figure 27	shows, in a detail drawing, the bottom view of a cover of an annular chamber; and
Figure 28	shows a schematic view of a part of the metering device of the previous figures in the closed state.

Like éléments, éléments of the same kind and identically acting éléments may be provided with the same reference numerals in the figures.

The metering device 1, e.g. an inhaler, which is illustrated In the figures and is intended for the inhalation of a powdery or pulvérulent substance 2, in particular a medical substance. The metering device 1 is preferably realized as a short-elongate device which can readily be carried in a pocket. The metering device 1 has a, preferably cylindrical, housing 3 which détermines its shape.

The, for example cylindrical, tube-like, housing 3 has, at its head end, an outer part or outer cylinder 4 which can be rotated about the device axis x relative to the housing 3. This outer cylinder is secured in a rotatable manner on the housing 3, such as in the région of an end-side radial step 5.

This likewise cylindrical, tube-like outer cylinder 4 merges, at the head end of the device 1, into an attached mouthpiece 6, which is formed appropriately for the mouth, i.e. which is, for example, flattened. This mouthpiece 6 can hâve a cup-like closure cap 7 engaging over it in a protective manner. This closure cap is realized as a screw cap, for the reason of which an associated internai thread 8 engages with a corresponding external thread 9 on the latéral wall of the housing 2.

The outer cylinder 4 is connected to the closure cap 7 in a rotationally fixed manner, for the reason of which the outer cylinder has, on the outside of its latéral wall, vertically oriented ribs 10 which interact with correspondingly positioned, slot-like vertical grooves 11 on the inside of the wall of the closure cap 7. Accordingly, screw-action actuation of the closure cap 7 causes the outer cylinder 4 to be rotated about the device axis x.

At the foot end, the end periphery of the cup-like closure cap 7 engages in a stoplimiting manner, and with sealing via a cône, against an annular shoulder 12. which is achieved on account of the above-mentioned step of the cylindrical housing 3.

The closure cap 7 serves, at the same time, as an actuating handle 13 for dispensing the pulvérulent substance 2 in reproducible sub-quantities 14, for the purpose of which use Is made of the axial screw-action displacement provided by the threaded engagement between the internai thread 8 and the extemal thread 9. The substance 2, e.g. comprising a powder, is accommodated (possibly such that it can be refilled) in a storage chamber 15 of the housing 3. The substance 2 may comprise or consist of the API(s) or the pharmaceutical composition described in more detail above or below. A metering device conveys a respective sub-quantity 14 of substance to a transfer location U located outside the storage chamber 15. For this purpose, a metering rod 33 may be movable such that a metering chamber 40 of the metering rod receives a subquantity ofthe substance 2 within the storage chamber 15, the sub-quantity being transported out of the storage chamber by relative movement of the metering chamber with respect to the storage chamber. The sub-quantity may be moved into the transfer location U by means of the metering chamber.

The meterable substance is a (usually médicinal) pulvérulent substance 2. It is possible for basic bodies such as lactose, which are capable for example of transporting a su et ion stream, to be carriers for fine micronized drug particles adhering to their surface.

The storage chamber 15 is terminated at the bottom by a cup-like pressure-exerting base 16, which is spring-loaded in the direction of the mouthpiece 6 by means of a compression spring 17. The base 16 thus forms a moveable wall of the storage chamber 15. The compression spring 17 has its foot-side end tum supported on a base cap 18, which closes the housing 3 there. This base cap is in latching engagement with that portion of the housing 3 which is of larger cross-section here on its inside wall, a corresponding latching collar 19 ofthe base cap 18 engaging in a matching annular groove of the housing 3.

The head-sideend tum ofthe biased compression spring 14 subjects an innershoulder 20 of a hollow piston 21 of the piston-like means 16/21 to loading action. As can be seen from the illustrations, the pressure-exerting base 16, which is in the form of a graduated cup, is connected by means of latching action to the hollow piston 21 in the région of the inner shoulder 20.

The cup periphery ofthe pressure-exerting base 16 forms an annular lip 22 which, on account of its elastomeric material, strips substance off the wall of the storage chamber without leaving any residues.

In the exemplary embodiment illustrated, the compression spring 17 is a cylindrical spring which, in its relaxed state, has a length corresponding approximately to ten times the maximum contact-pressure length. The contact-pressure length is defined by the 5 extent of axial displacement of the pressure-exerting base 16 between a lower position according to Figure 1, this position corresponding to the filling position, and an upper, stop-limited position ofthe pressure-exerting base 16 in the storage chamber 15 according to Figure 4. Thus, the exemplary embodiment illustrated provides a contactpressure length of 15 mm. As a resuit of the configuration of the spring, in particular as 10 a resuit of the selected length of the spring, the pressure-exerting base 16 is subjected to a constant spring pressure over the entire contact-pressure length, which causes the substance to be compressed uniformly throughout the duration of use of the device 1.

A hollow upright stub 23 extends centrally from the base cap 18. Together with the hollow piston 21, which encloses it at a distance apart, this hollow upright stub forms a chamber 24 for the compression spring 17. The hollow upright stub 23 contains, in its centre, a moisture-absorbing material in the form of a drying-agent capsule 25. At the transition to the outer cylinder 4, which follows the housing 3 in the axial direction, the storage chamber 15 terminâtes with a chamber ceiling 26 formed integrally with the latéral wall of the storage chamber 15. Passing through the centre of this chamber ceiling Is a cylinder portion 27 of a rotary part 28 which extends in a plane perpendicular to the device axis x.

This rotary part is of substantially plate-like configuration and is connected in a rotationally fixed manner to the outer cylinder 4 and, accordingly, can be rotated about the device axis x in relation to the chamber ceiling 26. The cylinder portion 27 extends on the underside of the rotary part 28, passing through the chamber ceiling 26. The lower free end surface of the cylinder portion 27 is located in the plane of that surface of the chamber ceiling 26 which covers the storage chamber 15.

The diameter ofthe through-opening in the chamberceiling 26 is largerthan the diameter of the cylinder portion 27. A holder, of annular shape in plan view, for a rotor blade R, is positioned in the annular gap which remains. This rotor blade is connected in a rotationally fixed manner to the cylinder portion 27.

The inner surface of the rotor ring 30, this inner surface being directed toward the storage chamber 15, is located in the plane of the correspondingly directed end surface of the cylinder portion 27.

The rotor R, which is illustrated on its own in Figures 22 and 23, carries on its underside, that is to say in the direction toward the storage chamber 15, a blade 29. This is a blade 29 which is in the form of a spherical-cap portion and projects radially outward beyond the ring 30 of the rotor R. The blade 29 correspondingly engages beneath that région of the chamber ceiling 26 which adjoins the rotor R radially on the outside, wherein that surface of the blade 29 which is directed toward the chamber ceiling 26 is of planar configuration. This surface of the blade 29 engages with the top surface of the chamber which is directed toward the blade. The blade 29 extends radially as far as the inner wall of the storage chamber 15. From this radial outer région, the blade 29 slopes up convexly in the radial inward direction, as seen in the cross-section, to an axial height corresponding approximately to the extent by which the blade 29 projects radially beyond the rotor ring 30.

As a resuit of this arrangement, the blade 29 of the rotor R projects into the substance stored in the storage chamber 15. The shoulder formed by the chamber ceiling 26, in interaction with the blade 29 or rotor R, which can be rotated relative to the storage chamber 15, forms a stator St.

The rotor R is clipped on the cylinder portion 27 of the rotary part 28 via the rotor ring 30.

The cylinder portion 27 accommodâtes a sealing bushing 31 at its centre. This bushing consists of a rubber material or a similar elastic material. This leaves, at its centre, a cross-sectionally slot-like guide opening 32 for the cross-sectionally adapted metering rod 33.

In the simplest configuration, the sealing bushing 31 and also an annular seal 35 provided between the rotary part 28 and a housing portion 34, which engages over the chamber ceiling 26 on the housing side, may be produced by two-component injection molding together with the rotary part 28 and, furthermore, with an inner cylinder, which will be described in more detail. It is, however, also possible in this respect for the rubber or elastomer parts to be provided subsequently during production.

At the foot end, the hollow piston 21, which is connected by means of latching action to the pressure-exerting base 16, has a radial extension arm 36. Integrally formed on the latter is an axially oriented indicating protrusion 37, which engages over the storagechamber wall on its outside. The axial position of this indicating protrusion, this position being reached in dependence on the position of the pressure-exerting base, can be seen by the user from the outside through a viewing window 38 provided in the housing. A ftlling-level indicator 39 is provided as a resuit.

The metering rod 33 is appropriately configured for functioning as a moving metering chamber 40 for the sub-quantity 14 of substance which is to be dispensed, the metering rod 33 moving linearly along the longitudinal centre axis x-x of the substantially rotationally symmetrical device 1, and this being accompanied by a rotary movement executed about the longitudinal centre axis x-x. The metering rod 33 is formed substantially as a fiat part with an elongate-rectangular cross-section. The length ratio of the short side to the long side is approximately 1:3 in the exemplary embodiment illustrated.

At the end which is directed away from the mouthpiece 6, the metering rod 33 forms a portion which tapers more or less in the manner of a cross-recessed screwdriver tîp. Here, the two mirror-symmetrical oblique flanks extend from the respective broad sides of the metering rod 33 (cf. Figure 20).

On account of the metering rod 33 being canried along in rotation, the cross-sectional configuration of the metering rod 33 and the tapering of the free end région hâve a loosening, displacing effect in the central région in relation to the mass of pulvérulent substance 2.

The metering chamber 40 is realized as a transverse hole which runs substantially perpendicular to the longitudinal centre axis x-x and has an axis which passes through the broad-side surfaces of the metering rod 33. The transverse hole is formed conically, so that the transverse hole tapers in the direction of one broad-side surface of the metering rod 33. Furthermore, as can be seen for example from the illustration in Figure 2, the metering chamber 40, which is formed in the région of that end of the metering rod 33 which projects into the mass of substance, is disposed eccentrically in relation to the broad-side surfaces of the metering rod 33, that is to say it is offset laterally in relation to the longitudinal axis x-x.

The displacement path of the metering chamber 40, which moves lineariy and, at the same time, in rotation, allows, in both end positions of the metering rod 33, for the cross-section of the guide opening 32 to be kept closed, with metering-chamber-filling scraping or stripping action over the length of said opening 33.

The mouthpiece end of the closure cap 7 forms a docking location 41 between the metering rod 33 and the closure cap 7, this docking location disengaging when subjected to overioading. The latching means on the closure-cap side here is a résilient hook annulus which is formed in the région of the free end of a hollow cylinder 43 disposed centrally on the underside of a closure-cap ceiling 42. The corresponding end of the metering rod 33 is rotationally symmetrical in cross-section, a disk-like radial collar 44, furthermore, projecting out in the transition région from the flat-part portion to the cylindrical end portion. At an axial spacing from this radial collar 44, that end région of the metering rod 33 which is directed away from the fiat part forms a latching head 45. A wasp-waist-like annular groove 46 is formed between this latching head and the radial collar 44. Inwardly directed noses 47 of the résilient tongues of the hook annulus engage in this annular groove. The noses 47 can pass over the latching head 45 in both axial directions. The latching action may be falrly tight, since it is released and reinstated during the screwing-action displacement of the cap.

The central opening 48 of the mouthpiece 6 is formed in the région of a dispersing part 49. This dispersing part 49 opens conically outward, that is to say in the direction away from the storage chamber 15, the wall 50 of the dispersing part merging, in the direction toward the storage chamber 15, into an annular, roof-like ceiling portion 51. At the same time, the latter forms the upper end of the outer cylinder 4, which cames the mouthpiece

6.

The central free space created by the dispersing part 49 has the hollow cylinder 43, which carries the noses 47, passing through it centrally in the cap-closed position. The annular space which is formed here between the hollow cylinder 43 and the dispersingpart wall is filled by a further drying-agent capsule 52 in the cap-closed position.

The outer part or outer cylinder 4 accommodâtes an inner part or inner cylinder 53, passing through the centre of which is the metering rod 33 and, in the cap-closed position, the hollow cylinder 43 belonging to the closure cap. The inner cylinder is connected in a rotationally fixed manner to the outer cylinder 4.

This inner cylinder 53 is configured substantially as a hollow body and carries, in its centre, an axially displaceable piston 54. The piston 54 is guided more or less in the lower half of the inner cylinder 53, directed toward the storage chamber 15, by a crosssectionally round guide portion 55.

That portion of the inner cylinder 53 which is directed away from the storage chamber 15 forms a piston-head displacement région 56 which has a cross-section larger than that of the guide portion 55 and the axially oriented wall 57 of which has radial openings 58, 58' and 58. These radial openings are in flow connection with a grille-wall portion 59 of the outer cylinder.

Formed beneath the grille-wall portion 59, and furthermore at the foot end of the guide portion 55 of the inner cylinder, is a radially oriented flow channel 60, which likewise opens toward the grille-wall portion 59. This flow channel may also serve as a window for visually monitoring the metering rod 33. It opens out into the free space left in the centre by the guide portion 55. Radially opposite the flow channel 60, the guide portion 55 is adjoined by an intermediate channel portion 61 which, starting from the guide portion 55 and with the inclusion of an angle of 45° in relation to a plane oriented perpendicularly to the axis x, slopes up in the direction of the associated wall of the outer cylinder 4 in order to then merge, at the end, into an axially directed channel 62. This channel 62 is formed by an axially oriented, slot-like, radially outwardly opening recess in the latéral surface of the inner cylinder. The channel 62 is covered radially by the associated wall of the outer cylinder 4.

As well as the radial opening 58, which can be seen by way of example in the sectional illustration in Figure 1, two further radial openings 58' and 58” are provided, and these each enclose, as seen in a plane oriented transversely to the axis x, an angle of 90’ in relation to this radial opening 58 and, by virtue ofthe inner-cylinderwall being configured appropriately, are in direct air-flow connection with the grille-wall portion 59.

The axially oriented channel 62 has its end which is directed toward the mouthpiece 6 opening out into an annular chamber 63. The latter forrns a vortex chamber. The ceiling 64 of the latter is of cross-sectionally roof-like configuration and is provided with peripherally extending, projecting wings 65,66. These engage peripherally against the inner wall of the outer cylinder 4 and, as seen in the circumferential direction, leave intermediate spaces 67 between them, through which an air-flow connection is achieved between the annular chamber 63 and a further annular space 68 left between the dispersing-part ceiling portion 51 and the annuiar-chamber ceiling 64.

The ceiling 64 is secured on the inside wall of the inner cylinder 53 by an axially directed flange 69.

The base of the annular chamber 63 is formed by an annular collar 70 which projects radially outward on the outside wall ofthe innercylinder 53 atan axial spacing from the wings 65, 66 of the ceiling 64. It is also the case that this annular collar is supported peripherally on the inside wall ofthe outer cylinder 4. This annular collar 70 is interrupted by the axially oriented channel 62. The annular chamber 63 is bounded in the radially inward direction by an end-side wall portion which belongs to the inner cylinder 53 and serves for latching the ceiling 64. The resulting annuiar-chamber wall is provided with slot-like through-passages 71 in order to provide air-flow connection between the annular chamber 63 and the piston-head displacement région 56.

As can furthermore be seen, in particular, from the sectional illustration in Figure 18, the outer-cylinder wall is provided, levei with the annular chamber 63, with two diametrically opposite air-inlet openings 72. These open out tangentially into the annular chamber 63, and this, furthermore, prédéterminés a common flow direction. Accordingly, a sucking-in action through the air-inlet openings 72 results in a predetermined air flow in the annular chamber 63. The axially oriented channel 62 opens out, as seen in the flow direction, immediately downstream of the mouth of one air-inlet opening 72 in the annular chamber 63, so that the airstream entering into the annular chamber 63 through the axial channel 62 is deflected specifically in the desired vortexing direction via the airinlet openings 72.

Thewings ofthe ceiling 64, as seen in the circumferential direction, are ofdifferent widths. Thus, two diametrically opposite wings 65 are approximately three times the width of the rest of the wings 66, as seen in the circumferential direction. One of these broader wings 65 covers over the mouth région of the axial channel 62 into the annular chamber 63 and, accordingly, forms a deflecting-wall wing 73 for the suction airstream entering into the annular chamber 63 through the axial channel 62.

As can further be seen, in particular, from the illustration in Figure 27, the wings 66 extend circumferentially, in the exemplary embodiment described, over an angle β of 15°. The intermediate spaces 67 left between the wings 66 and 65 likewise extend circumferentially over an angle a of 15°, while the peripheral edges of the broader wings 65 enclose an angle δ of 45°.

Other distributions are also possible in this respect (for example smaller wings - larger intermediate spaces; larger wings - smaller intermediate spaces; irreguiar configuration of wings and intermediate spaces).

An interrupter 74 is disposed in the annular chamber 63 adjacent to the mouth of the axial channel 62 in the annular chamber 63, the interrupter being in the airflow direction through the air inlet openings 72. This interrupter limits the circumferential path of the annular chamber 63 and accordingly, as a resuit of this configuration, this path is of an interrupted form rather than being annular throughout. The rear flank of the interrupter 74, this flank being oriented counter to the flow direction, constitutes a run-on slope 75, connecting the annular-chamber base to the annular-chamber ceiling, which contains the intermediate spaces 67. This causes the airstream in the end région of the annular chamber 63 to be forcibly deflected axially upward into the further annular space 68.

The piston 54, which is retained in a rotationally fixed but axially dtsplaceable manner in the inner cylinder 53, has, in the first instance, a piston head 76 which opens in disk form in the direction of the mouthpiece. This piston head opens conically in crosssection. Two parallel, axially oriented tongues 77 are integrally formed on the underside of the piston disk. The piston 54 consists of a rubber-like material.

Along their lower free periphery, the tongues 77, which accommodate the crosssectional contour of the guide portion 55 of the inner cylinder 53 on their outside wall, are split in a lip-like manner, and, furthermore, in their free peripheral région, they hâve material-reinforced sealing surfaces 78.

The fiat part of the metering rod 33 is guided between the tongues 77, the sealing surfaces 78, in interaction with the fiat part of the metering rod 33, having a stripping and sealing action.

ln a basic position of the device according to the illustration in Figure 1, the free périphéries of the tongues 77, these périphéries being split in a lip-like manner, engage, within an axial dépréssion, against the upper side of the cylinder portion 27.

Furthermore, in this basic position, the disk-like piston head 76 rests in a stop-limited manner on a base région of the piston-head displacement région 56. The encircling peripheral région of the free end of the piston head 76 engages with sealing action against the associated inner wall of the inner cylinder 53.

Furthermore, in this basic position, the head of the metering rod 33, that is to say the radial collar 44 and latching head 45 of the same, rests in the dépréssion created by the 25 disk-like configuration of the piston head 76.

The piston head 76 here is located at an axial distance beneath the ceiling 64.

The device 1 cited fonctions as follows:

In order to préparé for inhalation, the closure cap 7 is first of ail removed by unscrewing.

As the closure cap 7 is being unscrewed upwardly, the mentioned coupling results in the outer cylinder 4 being carried along in rotation and, via this outer cylinder, the inner cylinder 53, as well as, in the exemplary embodiment cited, ail those parts above the storage-chamber plane which are not connected in a rotationally fixed manner to the housing 3. Accordingly, the metering rod 33 is also carried along in rotation, and furthermore, the action of the closure cap 7 being unscrewed upwardly gives rise, at the same time, to axial displacement of the metering rod 33 via the docking location 41, which causes a helical displacement of the metering chamber 40 into the as yet closed emptying-standby position B according to the illustration in Figures 6 and 7, in which it is aligned with the flow channel 60.

By virtue of the metering chamber 40 being disposed eccentrically in relation to the axis of rotation of the metering rod 33, it is filled optimally as a resuit of penetrating helically through the mass of substance, expediently assisted by the rotor. The larger-diameter opening surface of the metering chamber 40 here is oriented in the direction of rotation.

The simultaneously rotating blade 29 of the rotor R here causes the surrounding mass of substance to be in a constantly loosened state, a shoveling effect being achieved. When the rotor R rotâtes in the opposite direction - as the closure cap 7 is being screwed on again - the blade 29 interacts with the stator St in order to scrape off substance 2 from the surface of the stator and to press the substance 2 down, as a resuit of which the mass of substance is evened out. The blade 29 of the rotor R, accordingly, acts on the mass of substance in both directions of rotation.

When the removal-standby position B of the metering rod 33 is reached, the metering rod is secured by means of latching action. For this purpose, the radial collar 44 of the metering rod 33 moves behind latching fingers 79 which are formed on the underside of the ceiling 64.

As the screwing-action displacement of the closure cap 7 continues, the latching in the région of the docking location 41 between the hollow cylinder 43 and the metering rod 33 is eliminated. Accordingly, the noses 47 leave the annular groove 46, whereupon the closure cap 7 can be removed. The device 1 is now prepared for inhalation.

The screwing-action displacement of the closure cap 7 allows for providing sufficient force for producing the latching between the radial collar 44 and latching fingers 79 and, furthermore, for eliminating the latching between the latching head 45 and noses 47 on the cap.

The tongues 77 ofthe piston 54 cover overthe metering chamber40 on each side. Accordingly, in this position, it is not possible for the sub-quantity 14 of substance to trickle out even in part. Rather, the substance is reliably held captive in the metering chamber 40. This prevents cases of double metering when inhalation is not carried out but the device is closed up again via the closure cap 7. Furthermore, in the removalstandby position B of the metering chamber 40, it is also possible for the device 1 to be put to one side. Even if the device 1 expériences normal kinds of impacts, this does notresuit in the sub-quantity 14 of substance which is to be inhaled trickling out, which would falsify the inhalation resuit.

The inhalation operation takes place automatically by the user subjecting the device to suction air, in the simplest case by the user breathing in.

Air is sucked in via the mouthpiece 6, and this, in the first instance, by virtue of the piston head 76 being subjected to the action of air, results in the piston 54 being displaced axially in the direction ofthe ceiling 64. In the case ofthe exemplary embodiment lllustrated, the pressure required to trigger the device is approximately 2 kgPa. Triggering takes place, as far as possible, in abrupt fashion. The inspiratory effort sign’rficantly changes once the piston has begun to move, thus indicating to the user that the inhalation is being performed correctly. Once the piston has assumed its raised position, the flow channel 60 through the metering chamber 40 towards the mouthpiece 6 is no longer blocked by the tongues 77.

In the raised position, the upper free peripheral région of the piston head 76 engages against the underside of an annular wall 80 ofthe ceiling 64. An audible feedback may be produced by the engagement. The annular space of the inner cylinder 53 which then encloses the free peripheral région of the piston head 76 is widened radially, as a resuit of which radial flow takes place around the piston 54 in the région of the piston head 76. This results in a main airstream a which flows through the grïlle-wall portion 59, passing through the radial openings 58, 58' and 58, into the piston-head displacement région 56 and passes, by way of the annular-space région left radially outside the piston head

76, through the openings 71 into the annular chamber 63. Approximately 85 to 90% of the total inhalation air volume is transportée! via this air-flow path.

At the same time, via the always open radial air-inlet openings 72, air is sucked in directly into the annular chamber 63, in order to prédéterminé the vortexing direction in the annular chamber 63.

By virtue of the axially displaced piston 54, the tongues 77 are likewise displaced axially in order to release the metering chamber 40. The axial displacement of the piston 54 is assisted by the guide portion 55, which accommodâtes the tongues 77, widening slightly in the direction of the piston head 76, as a resuit of which there is a réduction in the friction between the tongues 77 and the wall of the guide portion 55. It is also the case that the friction between the tongues 44 and the fiat part of the metering rod 33 is minimized to the région of the sealing surfaces 78.

The metering chamber 40 is then located in a removal-release position F, in which it lies freely in the flow path between the flow channel 60 and the intermediate channel portion 61. In the exemplary embodiment as illustrated, approximately 10 to 15% of the inhalation air volume is transported via this substance-transporting airstream b.

The metering chamber is cleared out with through-suction from the flow channel 60, this, furthermore, taking place from the smaller opening surface in the direction of the larger opening surface of the metering chamber 40. The two-fold deflection through approximately 45° in each case into the angled intermediate channel portion 61 and, from the latter, into the axially oriented channel 62 results, in the manner of a baffleplate effect, in the initial breaking-up of relatively large particies of powder, which further leads to an improved inhalation resuit.

The substance-laden airstream flowing axially, at relatively high speed, into the annular chamber 63 via the channel 62 is deflected via the deflecting-wall wing 73 and, assisted by the initial flow by way of the radial air-inlet openings 72, in the circumferential direction. Relatively large particies of powder are further broken up on this deflectingwall wing 73.

As a resuit of this configuration, the substance-laden airstream is guided outside the piston région. The piston 54 merely has powder-free airflowing around it.

Optimum distribution of the sub-quantity 14 of substance which is to be inhaled is achieved In the annular chamber 63. The substance-laden air passes out through the intermediate spaces 67 for inhalation. Relatively heavy particles of powder which hâve possîbly not been broken up or hâve not been sufficiently broken up are directed into the annular space 68 at the latest via the Interrupter 74.

In the annular chamber 63, the initially substantially axially infiowing airstreams a and b are directed in a common horizontal direction of circulation in order to then pass jointly into the mouthpiece 6, with axial passage through the ceiling 64.

A number of features for indicatîng successful inhalation to the user are provided. In the first instance, a Visual check can be carried out in that the piston 54, once raised by suction air, is retained in its raised position on account of the, albeît low, frictional forces présent. The piston 54, or the tongues 77 thereof, can be seen in the removal-standby position B through the radially outwardly open flow channel 60. This can be further assîsted by colouring the tongues 77 conspicuous, e.g. in green. Once inhalation has taken place and the piston 54 has been raised correspondingly, the tongues 77 can no longer be seen. Rather, there is a free view of the empty metering chamber 40. Also, the action of the piston 54 striking against the underslde of the sealing 64 can be sensed both acoustically and by touch.

Once inhalation has taken place, and alternatively also if it is not desired to effect inhalation from the removal-standby position B, the closure cap 7 is screwed on again, the latching between the radial collar44 and the latchîng fingers 79 being elimlnated in the first instance by virtue of the latching head 45 being acted upon by the noses 47. The retaining forces of this latching connection are of a correspondingly smaller magnitude than the amount of force which is necessary for deflecting the noses 47. As the action of screwing the closure cap 7 downward continues, the radial collar 44 on the metering rod displaces the piston 54 back again into its basic position. At the same time, with axial displacement and corresponding rotary movement, the metering rod 33 is displaced downward into the storage chamber. The action of the piston 54 being displaced back via the metering rod 33 terminâtes with the free ends of the tongues 77, which are formed in the manner of lips, striking against the facing ceiling surface of the cylinder part 27. As the downward-screwing displacement continues, the noses 47 finally enter into the annular groove 46 of the metering rod 33. This final latching action is discernable to the user acoustically and by touch, in order to indicate that the closing operation is completed. It is thus also ensured that a latching action between the metering rod 33 and closure cap 7 which causes the metering rod 33, and thus the metering chamber 40, to be carried along into the removal-standby position B is only achieved in the lowermost position of the metering rod 33, in which position the metering chamber 40 is filled. Accordingly, there is always a filled metering chamber 40 available when the metering rod 33 is raised.

Incorrect operation is reliably avoided. Improper closure of the device 1 means that, during the next attempt at inhalation, the metering rod 33, which accordingly has not been raised, on the one hand closes the passage between the flow channel 60 and the intermediate channel portion 61 by way of its flat-part portion. On the other hand, the metering rod 33 continues acting on the associated surface of the piston head 76 via the radial collar 44. Accordingly, when an attempt is made at inhalation, the closure of the flow channel 60 and the blocking of the piston 54 renders it impossible to build up any air flow (with the exception of the small amount of flow via the small radial air-inlet openings 72). This clearly signais incorrect positioning to the user. This can only be eliminated by the device 1 being properiy closed.

Figure 28 shows a schematic view of a part of the metering device of the previous figures in the closed state, where the closure cap is attached to the housing. In Figure 28, the closure cap 7 is connected to the housing 3. As is apparent from Figure 28, the closure cap 7 is provided with one or more first rotational stop features 81. The housing 3 is provided with one or more second rotational stop features 82. The first stop features 81 provide first stop faces 83, and the second stop features 82 provide second stop faces 84. The stop faces face in the angular direction. In the closed state of the metering device, the stop faces 84 and 83 abut. The stop faces extend in the axial direction whereas they are oriented in the angular direction such that, when the closure cap 7 is being attached to the housing 3, the stop faces are rotated towards each other, particularly near the end of the connection movement of connecting the closure cap 7 to the housing 3. When the stop faces 84 and 83 abut, the user can be sure that the correct end position ofthe closure cap has been reached. Likewise, the stop features 81 and 82 are visible from the outside so that a user can check whether the stop features are arranged correctly and whether the stop faces abut in order to confirm whether the closure cap has been applied correctly. The respective stop features may be disposed circumferentially along the housing or the closure cap, respectively. The respective stop feature may be embodied as a tooth having a steep side, which forms a stop face, and a less steep side. Steep sides and less steep sides may be disposed in an altematîng manner along the circumference ofthe cap or the housing, respectively. The slope of the less steep side may be determined by the thread by means of which the closure cap and the housing are connected.

There are considérable advantages of the pulmonary drug delivery:

- It requires a small fraction of delivery of oral dose.

- Rapid onset of action.

- Low concentration in the systemic circulation which are associated with reduced systemic side effects.

- Dégradation of drug by liver is avoided by this delivery method.

- This delivery is needle-free method.

- Gastrointestinal upset may be avoided.

Although any of the API(s) or compositions described herein above is suitable for being used in the présent device and may hâve certain advantages, it has been found that using the device described herein in conjunction with a particular composition is particularly advantageous as itimproves the bioavailabilty ofthe used APIs. Ifthe bioavailability of the APIs is improved in case of inhalable formulations the above advantages of pulmonary drug delivery are much more présent. There is a constant need to improve the bioavailability.

It has been examined how it is possible to improve the bioavailability of salmeterol xinafoate-fluticasone proprionate combinations using different inhalable dry powder formulations and different methods of their making.

It has been found that if the (i) first part of the carrier and of salmeterol xinafoate are blended together, (ii) second part of the carrier and fluticasone propionate are blended together a mixture is prepared, (iii) mixtures received in steps (i) and (ii) are blended together, and (iv) the received dry powder mixture in step (iv) is filled into the a dry powder inhaler then the received inhalable pharmaceutical compositions secure far better bioavailability of the APIs.

The blending can be performed by using a high shear mixer (Cyclomix Hosokawa) in for example a 5 liter vessel. The mixing speed (rounds per minute =rpm) can range from 250 to 350 rpm, preferably from 275 to 325 rpm, most preferred between 300 to 310 rpm. The mixing speed used for some of the examples is 305 rpm in a 5 liter vessel. The mixing time can be set to a time period of between 30 to 120 seconds, preferably between 40 to 90 seconds, most preferred between 50 to 70 seconds. The actual mixing time used in some of the examples is 60 seconds. The fill grade of the vessel can range from 20 to 90%, preferably 40 to 70%, and most preferred 50 to 60%, wherein the current setting for most of the examples is 58%.

Pharmaceutical compositions thus obtained may comprise 70 mass% - 99,5 mass% of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0,1 mass% -12,5 mass% of salmeterol xinafoate and 0,4 mass% - 17,5 mass% of fluticasone propionate.

Preferred group of pharmaceutical compositions thus obtained may comprise 88 mass% - 99,2 mass% of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0,3 mass% - 5,0 mass% of salmeterol xinafoate and

0,5 mass% - 7,0 mass% of fluticasone propionate.

Applied salmeterol xinafoate and fluticasone propionate may hâve different particle size distributions according to different Pharmacopeias. These active pharmaceutical ingrédients (APIs) having properties as described in European Pharmacopœia (Ph. Eur.) are well-applicable.

For the préparation of formulations according to the présent disclosure the pharmaceutically acceptable carriers may be among others lactose, glucose, maltose, fructose, sucrose, dextrose, their hydrates or mixtures thereof. Their particle size distributions may be different.

Carriers having properties as described in Ph. Eur. are generally applicable.

Particle size distribution may be measured for example by a dry method using laser light scattering in a Helios apparatus. This method is applicable in case of salmeterol xinafoate and fluticasone propionate as well.

Pharmaceutical formulations according to the présent disclosure may be used for the treatment of asthma, COPD and bronchitis. During the treatment the patient actuates the dry powder inhaler containing the composition of the disclosure and Inhales the pharmaceutical composition.

The pharmaceutical compositions of the disclosure as described above and below and optionally made by the process of the disclosure may be loaded in a dry powder inhaler. The inhaler may be a single dose inhaler or a multiple dose inhaler. As set forth herein, the inhaler described herein has particular advantages when being used with the pharmaceutical composition.

In the following, examples are given for the pharmaceutical composition:

Example 1:

Firstly 800g of lactose placed into the blender / Cyclomix Hosokawa equipment / after that 18g salmeterol xinafoate is added above the lactose layer. Further 800g of lactose are added into the blender (sandwich layering). The mixture is blended and the resulting blend is discharged and it is stored in a stainless steel container (pre-blend 1).

As a next step 175g of lactose is filled in an empty blender and 30g fluticasonpropionate is added onto the lactose layer. Further 175g of lactose is added into the blender (sandwich layer).

The layers are blended and the resulting blend is discharged and it is stored in a stainless steel container (pre-blend 2). Next a half of the pre-blend 1 is placed in a blender and pre-blend 2 is added to the pre-blend 1 and the second half of pre-blend 1 is placed to the layers (sandwich layer system) in the blender. Layers are blended together and the resulted blend is sieved and filled - using a volumétrie screw - into the réservoir or storage chamber of the dry powder inhaler Approximately 1800 units may be filled into the devices using volumétrie screw.

The spécifications of the used APIs and the carrier are as follow:

Lactose monohydrate Ph.Eur PSD : D10:60-115 um, D50=135-200 um, D90 is bigger than 220 um;

Salmeterol xinafoate Ph.Eur PSD : D10<2 um, D50: 3-6 um, D90<20 um, D99<50 um; Fluticasone propionate Ph.Eur PSD : D10<1,3 um, D50<4,0 um, D90<10 um, D99<50 um;

Example 2:

Pharmacokinetic data of an assembly for an inhaler according to the different embodiments of the invention described above together with the different variants of the pharmaceutical composition of the invention including salmeterol xinafoate and fluticasone proprionate were determined in comparison to the pharmacokinetic data of a conventional assembly including a disk-shaped inhaler housing a mixture of salmeterol xinafoate and fluticasone proprionate. Such a disk shaped inhaler is for example described in the PCT application WO 2001/97886 A1.

ln particular, the fine particle dose (FPD), which is the amount of particles with an aerodynamic diameter of between 1 to 5 pm, the area under the curve (AUC), corresponds to the intégral of the plasma concentration of an administered pharmaceutical drug substance versus an interval of definite time and Cmax, which is the maximum concentration measured for a pharmaceutical in the blood of test persons after it was administrated and prior to the administration of a second dose, were determined.

The below table shows a comparison of the ratio of these pharmacokinetic parameters for the assembly of the invention (invention) in relation to the conventional assembly (conventional):

Ratio invention/conventional FPD 1-5 pm	Ratio invention/conventional Point estimate AUC	Ratio invention/conventional Point estimate Cmax
Salmeterol	Fluticasone	Salmeterol	Fluticasone	Salmeterol	Fluticasone
0,90	0,93	1,25	1.42	1,69	1,66

It can clearly be seen that both the assembly according to the invention as well as the conventional assembly hâve similar fine particle doses, owing to the fact that the ratio for both Salmeterol and Fluticasone is nearly 1. Nevertheless, the ratio for the AUC and the Cmax is well above one, showing that the concentration of both pharmaceuticals in the blood depending on the time of administration and the maximum concentration of the pharmaceutical after administration (Cmax) is higher for the assembly according to the invention than for the conventional assembly. The bioavailability of the assembly of the invention is therefore increased in comparison to the conventional assembly. Without being bound by any theory, the inventors believe that one of the reasons for the higher bioavailability of the assembly of the invention could be the different inhalation flows of both assemblies (assembly of the invention has an inhalation flow of 65 l/mîn. at 4KPa, whereas the conventional assembly exhibits a flow of 90 l/mîn.). Due to the lower inhalation flow, the impact on the throat appears to be less for the assembly of the invention, which could lead to a higher absorption rate, ln addition the piston being actuatable by the user suction action also might provide a more constant dose of the pharmaceutical composition to a patient only if an appropriate flow rate is applied via the suction of the patient.

Ail features disclosed are (in themselves) pertinent to the invention. The disclosure content of the associated/attached priority documents (copy of the prior application) is hereby also included in full in the disclosure of the application, also for the purpose of incorporating features of these documents in claims of the présent application.

Reference numérale

Device

Substance

Housing

Outer cylinder

Radial step

Mouthpiece

Closure cap

Internai thread

External thread

Ribs

Grooves

Annular shoulder

Actuating handle

Sub-quantity of substance

Storage chamber

Pressure-exerting base

Compression spring

Base cap

Latching collar

Inner shoulder

Hollow piston

Annular lip

Upright stub

Spring chamber

Drying-agent capsule

Chamber ceiling

Cylinder portion

Rotary part

Blade

Rotor ring

Sealing bushing

Guide opening Metering rod Housing portion Annular seal Radial extension arm Indicating protrusion Viewing window Filling-level indicator Metering chamber Docking location Closure-cap ceiling Hollow cylinder Radial collar Latching head Annular groove Noses Mouthpiece opening Dispersing part Wall Ceiling portion Drying-agent capsule Inner cylinder Piston Guide portion Piston-head displacement région Région wall

Radial opening Radial opening Radial opening Grille-wall portion Flow channel Intermediate channel portion Channel

Annular chamber

Ceiling

Wing

Wing

Intermediate spaces

Annular space

Flange

Annular collar

Openings

Air-inlet openings Deflecting-wali wing Interrupter Run-on slope Piston head Tongues

Sealing surfaces

Latching finger

Annular wall Stop feature Stop feature Stop face Stop face

Device axis

Removal-standby position Removal-release position Rotor

Stator

Transfer location

Angle of intermediate spaces 67

Angle of wings 66

Angle of wings 65 a Main airstream b Substance-transporting airstream

Claims (14)

1. An assembly for an inhaler, comprising:

5 - a storage chamber, in which a powdery substance is arranged;

- a mouthpiece;

- a metering rod provided with a metering chamber, the metering chamber being movable relative to the storage chamber to retrieve a sub-quantity of the powdery substance from the storage chamber and to move the sub-quantity into a transfer

10 location outside the storage chamber, wherein, in the transfer location, the sub-quantity is arranged to be retrieved from the metering chamber and to be moved to the mouthpiece by a suction airstream which is generatable by a user suction action which is performed for an inhalation, the suction airstream flowing through a flow channel which is establishable between an air inlet ofthe assembly and the mouthpiece;

15 - a piston which is movable relative to the metering rod between a blocking position, in which the flow channel is blocked by the piston, and a non-blocking position, in which air is permitted to flow from the air inlet to the mouthpiece via the flow channel, the movement of the piston being actuatable by the user suction action; and

- the powdery substance comprising as a pharmaceutically active ingredient-pair 20 salmeterol xinafoate/fluticasone propionate.

2. The assembly of claim 1, wherein the assembly further comprises a closure cap which covers the mouthpiece and wherein the closure cap is releasably connected to the metering rod, such that a 25 movement of the closure cap to uncover the mouthpiece is converted into movement of the metering rod in order to move the metering chamber into the transfer location, and such that the connection between the metering rod and the closure cap is released when the metering chamber has reached the transfer location, thereby disconnecting the closure cap from the remainder of the assembly.

3. The assembly of claim 2, wherein, when the closure cap is re-connected to the remainder of the assembly, the connection between the closure cap and the metering rod is re-established, the metering chamber is moved again into the storage chamber and, when the connection t

is re-established, an audible and/or tactile feedback is generated, thereby indicating that the closure cap has been re-connected correctly and that the assembly is ready to move the dosing chamber again from the storage chamber into the transfer location.

5 4. The assembly of claim 2 or 3, wherein the piston is retained in the non-blocking position after the user suction action at least until the closure cap is being re-connected to the remainder of the assembly.

5. The assembly of any one of claims 2 to 4,

10 wherein the assembly comprises a housing and an outer part which are rotatably connected to one another but axially secured with respect to each other, the mouthpiece being provided on the outer part and the closure cap being releasably connected to the housing when the closure cap is connected to the remainder of the ' assembly.

6. The assembly of claim 5, wherein disconnection of the closure cap from the housing requires rotational movement of the closure cap with respect to the housing, wherein the closure cap is rotationally locked to the outer part such that the outer part rotâtes together with the 20 closure cap when the closure cap is disconnected from the housing.

7. The assembly of claim 5 or 6, wherein the metering rod is rotated and moved axially with respect to the housing when the metering chamber is moved from the storage chamber into the transfer location.

8. The assembly of any one of the preceding claims, wherein the outer part is covered by the closure cap when the closure cap is connected to the housing.

30

9. The assembly of any one of the preceding claims, comprising a first rotational stop feature on the closure cap providing a first rotational stop face, and a second rotational stop feature on the remainder of the device providing a second rotational stop face, wherein the first and second stop faces

- extend in the axial direction, t

- face in the angular direction, and

- are désignée) to abut when the closure cap has reached its end position upon being reconnected to the remainder of the assembly in order to indicate that the closure cap has reached its end position, wherein the first and second rotational stop features are arranged to be visible when the first and the second stop features abut.

10. The assembly of any one of the preceding claims, which is configured to provide one or more operational feedbacks, such as audible, Visual, tactile and/or inspiratory feedback, to the user which indicate to the user that the inhalation is being performed correctly or has been performed correctly.

11. The assembly of any one of the preceding claims, comprising a window which allows a Visual check to confirm whether the assembly is in a ready-to-inhale state or not.

12. The assembly of any one of the preceding claims, wherein the mouthpiece is differently coloured than the région of the device which adjoins the mouthpiece.

13. The assembly of any one of the preceding claims, comprising an indicator which provides information about the amount of powdery substance remaining in the storage chamber, wherein the indicated information is information directly resulting from the filling level of the storage chamber.

14. The assembly of any one of the preceding claims, wherein the powdery substance comprises a pharmaceutical composition comprising 70 mass% - 99,5 mass% of pharmaceutically acceptable carrier suitable for use in dry powder inhalation formulation and 0,1 mass% -12,5 mass% of salmeterol xinafoate and 0,4 mass% -17,5 mass% of fluticasone propionate.

15. An inhaler comprising the assembly of any one of the preceding claims.